Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62020TA0239

    Case T-239/20: Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA) (EU trade mark — Opposition proceedings — Application for the EU word mark RUXXIMLA — Earlier EU word mark RUXIMERA — Relative ground for refusal — Likelihood of confusion — Similarity of the signs — Article 8(1)(b) of Regulation (EU) 2017/1001)

    IO C 2, 3.1.2022, p. 30–30 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    3.1.2022   

    EN

    Official Journal of the European Union

    C 2/30


    Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA)

    (Case T-239/20) (1)

    (EU trade mark - Opposition proceedings - Application for the EU word mark RUXXIMLA - Earlier EU word mark RUXIMERA - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation (EU) 2017/1001)

    (2022/C 2/39)

    Language of the case: English

    Parties

    Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)

    Defendant: European Union Intellectual Property Office (represented by: D. Gája, acting as Agent)

    Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)

    Re:

    Action brought against the decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 (Case R 1879/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Stada Arzneimittel AG to pay the costs.


    (1)  OJ C 209, 20.6.2020.


    Top